UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/18.06.25 Stock UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/18.06.25
Add to a list
To use this feature you must be a member
Log inSign up

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/18.06.25 Stock

Warrant

DE000HC7U383

Market Closed - BOERSE MUENCHEN 03:41:55 2024-05-28 pm EDT
1.58 EUR -16.40% Intraday chart for UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/18.06.25
Current month+110.67%
1 month+81.61%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/18.06.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
Vertex to Participate in Upcoming June Investor Conferences BU
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT
More news

Quotes 5-day view

Date Price Change
24-05-28 1.58 -16.40%
24-05-27 1.89 +2.16%
24-05-24 1.85 +10.78%
24-05-23 1.67 +4.37%
24-05-22 1.6 +8.11%

Real-time BOERSE MUENCHEN

Last update May 28, 2024 at 03:41 pm EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
IssuerLogo Issuer UniCredit UniCredit
WKN HC7U38
ISINDE000HC7U383
Date issued 2023-06-30
Strike 600 $
Maturity 2025-06-18 (386 Days)
Parity 10 : 1
Emission price 1.6 €
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.77 €
Lowest since issue 0.66 €
Delta0.25x
Omega 6.557
Premium38.09x
Gearing26.13x
Moneyness 0.7448
Difference Strike 153.1 $
Difference Strike %+25.52%
Spread 0.03 €
Spread %1.89%
Theoretical value 1.575
Implied Volatility 28.54 %
Total Loss Probability 83.27 %
Intrinsic value 0.000000
Present value 1.575
Break even 617.10 €
Theta-0.04x
Vega0.13x
Rho0.09x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9 USD
Average target price
462.8 USD
Spread / Average Target
+3.57%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant